|
KROS Keros Therapeutics Inc 1664710 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-28,710,000.00 |
| Balance Sheet |
|
Current Assets
|
$266,883,000.00 |
|
Assets
|
$287,600,000.00 |
|
Current Liabilities
|
$12,153,000.00 |
|
Liabilities
|
$25,280,000.00 |
|
Equity
|
$262,320,000.00 |
|
Shares Out
|
19827188.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-23,950,000.00 |
|
Investing Cash Flow
|
$-228,000.00 |
| Market Analysis |
Market Cap
|
$217,107,708.60 |
|
Price
|
$10.95 |
|
BVPS
|
13.23 |
|
PB
|
0.83 |
|
EPS
|
-1.45 |
|
PS
|
151.36 |
|
FCF
|
$-24,178,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:47 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:37 |
|
| Apr |
May |
Jun |
| 2026-03-04 |
-0.86 |
|
|
2026-05-14 |
-1.21 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-06 |
-0.76 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-05 |
-0.18 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view KROS documents filed with the SEC.
KROS Filings
Clear
